1. 1 CHAI ARV Procurement Database Clinton Foundation HIV/AIDS Initiative November 7, 2005

2. The Clinton Foundation monitors ARV orders placed under our agreements for several reasons: Monitor pricing to determine if countries are accessing CHAI prices Monitor lead times between order placement and delivery Track quantities purchased under CHAI agreements Provide feedback to partner suppliers and organizations

3. The order tracking database strives to capture similar data items as the GPRM Purchasing country Purchasing agent Order number Order date Invoice date Manufacturer Factory Product number Batch Expiration date Generic name Acronym Brand Form Concentration Pack Size Number of packs US$/pack Total US$/pack (inc. S&H)

4. Currently the database contains information on 25 countries, capturing 185,000 patient years of treatment

5. No. of patients/years by API% of total volume of patients/years Lamivudine200.94833,0% Nevirapine173.00228,4% Stavudine165.16127,1% Zidovudine43.9467,2% Efavirenz16.2052,7% Didanosine2.1080,4% Ritonavir2.6010,4% Lopinavir1.5700,3% Nelfinavir1.9690,3% Indinavir1.0470,2% Abacavir5880,1% Tenofovir2020,03% Emtricitabine-- Atazanavir-- Saquinavir-- Delavirdine-- Amprenavir-- The overall results reveal that stavudine, lamivudine and nevirapine are the most commonly procured 1 st line drugs

6. Fixed dose combinations make up 55% of the total volume of formulations procured 1 st Line Single Pills d4t+3TC+ NVP 2 nd Line AZT+3TC d4t+3TC AZT+3TC+NVP The fixed dose formulation of d4t+3TC+NVP was ordered with highest frequency (45% of total volume) AZT+3TC was the second most common fixed dose ordered, at 9% Single pill formulations of the 1 st line drugs (AZT, d4t, 3TC, NVP and EFV) make up 39% of total volume

7. Regionally, the data reveals that the Latin American market may behave differently than the African market Stavudine vs. Zidovudine (% of total volume) 2 nd Line Uptake (% of total volume) d4t AZT 1 st Line 2 nd Line

8. Pediatric order data reveals that syrups are procured in higher volume than pills *Includes CHAI procurement in: Cambodia, China, DR, India, Kenya, Lesotho, Malawi, Namibia, Rwanda, Tanzania, Uganda, Zambia, Zimbabwe; Does not include 2 nd Line drugs, comprising an additional 20 – 30% of volume # of pills (millions) ml of solution (millions) Solution Pills

9. 9 Pediatric patients are expected to comprise 10% of total people on treatment by 2008 Number of patients (000s), select CHAI Consortium Countries* *Includes: Angola, Bahamas, Brazil, Cambodia, China, DR, Ethiopia, Haiti, India, Jamaica, Kenya, Lesotho, Mozambique, OECS, Rwanda, Tanzania, Zambia Adults Children